Cingulate Inc. (NASDAQ:CINGW) Sees Large Growth in Short Interest

Cingulate Inc. (NASDAQ:CINGW) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,149 shares, an increase of 283.0% from the June 30th total of 300 shares. Based on an average daily volume of 6,798 shares, the days-to-cover ratio is currently 0.2 days.

Cingulate Stock Down 7.2%

Shares of CINGW opened at $0.02 on Tuesday. The business’s 50-day moving average is $0.02 and its two-hundred day moving average is $0.04. Cingulate has a fifty-two week low of $0.02 and a fifty-two week high of $0.16.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.